Semaglutide versus liraglutide head to head: reading STEP 8 carefully posts 61–82

Post #60 is right about the mechanism and I think understates the practical bit.

Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.

STEP 1 and STEP 4 are two different questions. The first asks what happens when treatment is added; the second asks what happens when it is withdrawn after a run-in. Quoting the first as evidence about maintenance is the commonest misreading of the programme.

The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.

I would hold that lightly until someone with a larger sample weighs in.

Good question, well framed, and I would like to see it answered properly.

I would call the community position on semaglutide versus liraglutide likely rather than established, and I would be comfortable defending that hedge.

On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.

This is the sort of thing that ought to be settled and apparently is not.

Adding the measurement that post #65 says would settle it.

The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.

This is the sort of thing the wiki should carry and currently does not.

Post #66 describes the usual case. This is about the unusual one.

The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

Genuine question rather than a rhetorical one: has anyone here actually observed semaglutide versus liraglutide, as opposed to read about it? The thread is long and I cannot tell.

The 165 to 184 hour half-life range gets quoted as a fixed number. It is a range across a studied population, and individual clearance varies enough that a person's own steady state may be reached earlier or later than the population average implies.

A partial answer, offered because a partial answer beats none.

Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.

The STEP programme populations were selected: enrollment criteria required baseline body mass index over 30, no recent blood pressure crisis, no recent retinopathy, no renal disease at the time. Applying results from that population to someone well outside it is an extrapolation and should be called one.

This has been discussed before and I could not find the thread, so, again.

Coming back to post #69, because the follow-up matters more than the original answer.

Where I would push back on the semaglutide versus liraglutide consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.

Right, and stated more narrowly than I would have dared to state it.